SCHEMBL4874531

SCHEMBL4874531

CCOC(=O)c1cc(C#N)c(Cl)nc1Cl

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 13/20 0.60
HSD17B10 Q99714 3/20 0.60
L3MBTL1 Q9Y468 7/20 0.58
GAA P10253 1/20 0.58
ALDH1A1 P00352 12/20 0.53
MAPT P10636 4/20 0.53
KMT2A Q03164 3/20 0.53
MEN1 O00255 2/20 0.53
RXFP1 Q9HBX9 1/20 0.53
TDP1 Q9NUW8 6/20 0.50
NPSR1 Q6W5P4 4/20 0.49
HTT P42858 1/20 0.49
GPR55 Q9Y2T6 1/20 0.49
TSHR P16473 1/20 0.48
MAPK1 P28482 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
CASP1 P29466 1/20 0.48
LMNA P02545 4/20 0.47
HPGD P15428 4/20 0.47
CYP1A2 P05177 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3227432 0.90 KDM4E (0.71) KDM4EHSD17B10L3MBTL1GAAALDH1A1
SCHEMBL30782359 0.90 KDM4E (0.63) KDM4EHSD17B10L3MBTL1GAAALDH1A1
SCHEMBL2225084 0.90 KDM4E (0.63) KDM4EHSD17B10L3MBTL1GAAALDH1A1
SCHEMBL4109638 0.87 L3MBTL1 (0.57) KDM4EHSD17B10L3MBTL1GAAALDH1A1
SCHEMBL3328003 0.86 KDM4E (0.55) KDM4EHSD17B10L3MBTL1GAAALDH1A1
SCHEMBL26784521 0.85 KDM4E (0.54) KDM4EHSD17B10L3MBTL1GAAALDH1A1
SCHEMBL4875503 0.85 KDM4E (0.54) KDM4EHSD17B10L3MBTL1GAAALDH1A1
SCHEMBL4112789 0.85 KDM4E (0.54) KDM4EHSD17B10L3MBTL1GAAALDH1A1
SCHEMBL3581480 0.85 KDM4E (0.54) KDM4EHSD17B10L3MBTL1GAAALDH1A1
SCHEMBL30918308 0.84 KDM4E (0.63) KDM4EHSD17B10L3MBTL1GAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4651907-A1 DRUG CONJUGATES AND METHODS OF PREPARING AND USING THE SAME Adcentrx Therapeutics Inc. (US) 2025-11-26 EP disclosed
CN-118459440-A Preparation method and application of tetra-substituted aryl compound 江苏普莱医药生物技术有限公司 2024-08-09 CN disclosed
WO-2024155761-A1 DRUG CONJUGATES AND METHODS OF PREPARING AND USING THE SAME ADCENTRX THERAPEUTICS INC. (US) 2024-07-25 WO disclosed
EP-3822270-A1 NOVEL HETEROCYCLE DERIVATIVE JW Pharmaceutical Corporation (KR) 2021-05-19 EP disclosed
US-9902688-B2 Benzamides and nicotinamides as Syk modulators PORTOLA PHARMACEUTICALS, INC. (US) 2018-02-27 US disclosed
US-9902688-B2 Benzamides and nicotinamides as Syk modulators PORTOLA PHARMACEUTICALS, INC. (US) 2018-02-27 US disclosed
EP-3176154-A1 BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS Portola Pharmaceuticals, Inc. (US) 2017-06-07 EP disclosed
US-20160318852-A1 BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS ALEXION PHARMACEUTICALS, INC. 2016-11-03 US disclosed
US-20160318852-A1 BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS ALEXION PHARMACEUTICALS, INC. 2016-11-03 US disclosed
US-9359375-B2 Benzamides and nicotinamides as Syk modulators PORTOLA PHARMACEUTICALS, INC. (US) 2016-06-07 US disclosed
US-9359375-B2 Benzamides and nicotinamides as Syk modulators PORTOLA PHARMACEUTICALS, INC. (US) 2016-06-07 US disclosed
US-20150038492-A1 BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS ALEXION PHARMACEUTICALS, INC. 2015-02-05 US disclosed
US-20150038492-A1 BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS ALEXION PHARMACEUTICALS, INC. 2015-02-05 US disclosed
US-8846928-B2 Benzamides and nicotinamides as Syk modulators PORTOLA PHARMACEUTICALS, INC. (US) 2014-09-30 US disclosed
US-8846928-B2 Benzamides and nicotinamides as Syk modulators PORTOLA PHARMACEUTICALS, INC. (US) 2014-09-30 US disclosed
US-20120142671-A1 BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-06-07 US disclosed
US-20120142671-A1 BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-06-07 US disclosed
US-20080312208-A1 Pyridine Analogues ASTRAZENECA AB (SE) 2008-12-18 US disclosed
EP-1904474-A1 NEW PYRIDINE ANALOGUES AstraZeneca AB (SE) 2008-04-02 EP disclosed
WO-2007008140-A1 NEW PYRIDINE ANALOGUES ASTRAZENECA AB (SE) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142671-A1 BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS SYK, BTK, NADK KDM4E 1281/4885HSD17B10 3122/4885L3MBTL1 4503/4885
US-20160318852-A1 BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS SYK, BTK, NADK KDM4E 1281/4885HSD17B10 3122/4885L3MBTL1 4503/4885
US-20080312208-A1 Pyridine Analogues P2RY12, P2RY11, P2RY1 KDM4E 1759/4885HSD17B10 3283/4885L3MBTL1 4857/4885
US-20150038492-A1 BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS SYK, BTK, NADK KDM4E 1281/4885HSD17B10 3122/4885L3MBTL1 4503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.